Nivolumab/Cisplatin/Radiotherapy Improves DFS in Locally Advanced SCCHN
The phase 3 NIVOPOSTOP GORTEC 2018-01 trial shows that nivolumab added to radiotherapy and cisplatin had improved efficacy over SOC treatments in SCCHN.
Related Articles
Genetic Ancestry–Based Differences in Biomarker-Based Eligibility for Precision Oncology Therapies
This cohort study examines if the approval of precision oncology therapies has benefited patients with cancer from various ancestral backgrounds equally over time.
ctDNA Testing Joins NCCN Guidelines for MRD Assessment in DLBCL
The NCCN Guidelines for B-Cell Lymphomas were updated to include ctDNA testing for MRD assessment for patients with PET-positive DLBCL at end of treatment.
Combination extends survival vs. standard first-line therapy for advanced lung cancer
A two-drug combination extended OS compared with standard first-line osimertinib for certain patients with advanced lung cancer, according to the agents’ manufacturer.The OS benefit with…
Sasanlimab Plus BCG Meets EFS End Point in BCG-Naive, High-Risk NMIBC
Sasanlimab plus BCG improved event-free survival in BCG-naive, high-risk non–muscle-invasive bladder cancer.
p53 expression in cytology samples may represent a marker of early‐stage cancer
p53 might be useful in discriminating thyroid follicular lesions. p53 is likely to be a useful diagnostic marker in recognizing indeterminate lesions that are well-differentiated…
Marching through a testicular cancer diagnosis
Grayson Niemi juggled chemo treatments for testicular cancer and practice sessions for joining Ohio State’s marching band. He made the band and also to the…
Coping with Cancer After a Natural Disaster: Frequently Asked Questions for Cancer Patients and Their Caregivers
If you (or a loved one) have cancer and your treatment plan needs to change due to a recent natural disaster, the following questions and…
FDA grants fast track designation for LYT-200 in R/R AML and MDS
On January 9, 2025, the U.S. Food and Drug Administration granted fast track designation for LYT-200, a first-in-class anti-galectin-9 mAb, for the treatment of patients…
Leonard and Norma Klorfine Endowed Chair for Clinical Research awarded to Dr. Geoffrey Hill
Geoffrey Hill, MD, FRACP, FRCPA, was recently announced as the recipient of the Leonard and Norma Klorfine Endowed Chair for Clinical Research at Fred Hutch…
